These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 7379312)

  • 1. Evidence for dopamine as an inhibitor of vasoprotein release in man.
    Lightman SL; Forsling M
    Clin Endocrinol (Oxf); 1980 Jan; 12(1):39-46. PubMed ID: 7379312
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of dopamine in the inhibition of vasopressin secretion by L-dopa in carbidopa-treated dogs.
    Reid IA; Chou L; Chang D; Keil LC
    Hypertension; 1986 Oct; 8(10):890-6. PubMed ID: 2875946
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blood pressure and vasopressin in progressive autonomic failure. Response to postural stimulation, L-dopa and naloxone.
    Puritz R; Lightman SL; Wilcox CS; Forsling M; Bannister R
    Brain; 1983 Jun; 106 (Pt 2)():503-11. PubMed ID: 6850280
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evidence for a functional central dopaminergic insufficiency in the spontaneously hypertensive rat.
    Hutchinson JS; DiNicolantonio R; Veroni M; Cleverdon M
    Clin Exp Pharmacol Physiol; 1983; 10(3):311-4. PubMed ID: 6627745
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Studies on the responses of plasma renin activity and aldosterone and cortisol levels to dopaminergic and opiate stimuli in man.
    Lightman SL
    Clin Endocrinol (Oxf); 1981 Jul; 15(1):45-52. PubMed ID: 7030527
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of L-dopa with and without decarboxylase inhibitor on growth hormone secretion in children with short stature.
    Fevang FO; Stoa RF; Thorsen T; Aarskog D
    Acta Paediatr Scand; 1977 Jan; 66(1):81-4. PubMed ID: 831384
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of dopamine on neurohypophysial hormone release in vivo and from the rat neural lobe and hypothalamus in vitro.
    Bridges TE; Hillhouse EW; Jones MT
    J Physiol; 1976 Sep; 260(3):647-66. PubMed ID: 988183
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Central cardiovascular effects of L-DOPA and clonidine in the lizard, Agama caudospinosa.
    Johansson P
    Acta Physiol Scand; 1982 Sep; 116(1):37-40. PubMed ID: 7158390
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protective effects of L-dopa and carbidopa combined treatments on human catecholaminergic cells.
    Colamartino M; Padua L; Meneghini C; Leone S; Cornetta T; Testa A; Cozzi R
    DNA Cell Biol; 2012 Nov; 31(11):1572-9. PubMed ID: 23020119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of high single doses of levodopa and carbidopa on brain dopamine and its metabolites: modulation by selective inhibitors of monoamine oxidase and/or catechol-O-methyltransferase in the male rat.
    Männistö PT; Tuomainen P
    Naunyn Schmiedebergs Arch Pharmacol; 1991 Oct; 344(4):412-8. PubMed ID: 1766471
    [TBL] [Abstract][Full Text] [Related]  

  • 11. L-dopa hypotension in dogs: evidence for mediation through 5-HT release.
    Antonaccio MJ; Robson RD
    Arch Int Pharmacodyn Ther; 1974 Nov; 212(1):89-102. PubMed ID: 4281293
    [No Abstract]   [Full Text] [Related]  

  • 12. Loss of central nervous system component of dopaminergic inhibition of prolactin secretion in patients with prolactin-secreting pituitary tumors.
    Fine SA; Frohman LA
    J Clin Invest; 1978 Apr; 61(4):973-80. PubMed ID: 659585
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of L-dopa on vasopressin secretion in man [proceedings].
    Forsling ML; Lightman SL
    J Physiol; 1979 Jul; 292():64P-65P. PubMed ID: 490401
    [No Abstract]   [Full Text] [Related]  

  • 14. Effect of the dopa decarboxylase inhibitor MK-486 on L-dopa-induced inhibition of prolactin secretion: evidence for CNS participation in the L-dopa effects.
    Szabo M; Nakawatase C; Kovathana N; Frohman LA
    Neuroendocrinology; 1977; 24(1):24-34. PubMed ID: 600362
    [No Abstract]   [Full Text] [Related]  

  • 15. Dopamine and L-dopa: inhibition of thyrotropin-stimulated thyroidal thyroxine release.
    Maayan ML; Sellitto RV; Volpert EM
    Endocrinology; 1986 Feb; 118(2):632-6. PubMed ID: 2867890
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Age-dependent depressor effect of L-dopa in dogs with inhibition of extracerebral dopa decarboxylase.
    Wilke WL
    Pediatr Res; 1983 Nov; 17(11):924-5. PubMed ID: 6359046
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Further evidence on the direct action of L-Dopa on prolactin release.
    Donoso AO; Banzán AM; Barcaglioni JC
    Neuroendocrinology; 1974; 15(3-4):236-9. PubMed ID: 4420786
    [No Abstract]   [Full Text] [Related]  

  • 18. Effect of L-dopa with and without inhibition of extra cerebral dopa decarboxylase on gastric acid secretion and gastrin release in man.
    Caldara R; Barbieri C; Piepoli V; Borzio M; Masci E
    Gut; 1985 Oct; 26(10):1014-7. PubMed ID: 4054700
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of plasma osmolality, angiotensin II and dopamine in vasopressin release in man.
    Morton JJ; Connell JM; Hughes MJ; Inglis GC; Wallace EC
    Clin Endocrinol (Oxf); 1985 Aug; 23(2):129-38. PubMed ID: 4053411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of the methionine enkephalin analogue DAMME on the vasopression response to tilt in man.
    Lightman SL; Forsling ML
    Clin Sci (Lond); 1980 Dec; 59(6):501-3. PubMed ID: 7438715
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.